Forbes July 29, 2024
Charles Wetzel, CEO of Kalibrate, retail analytics to help decision makers understand potential, manage risk and outperform the competition.
In May, owners of pharmaceutical company Novo Nordisk revealed that more than 25,000 people a week are signing up to use its weight loss drug Wegovy in the U.S.
The pharmaceutical is designed to help conditions such as obesity, high blood pressure, high cholesterol and Type 2 diabetes, suppress feelings of hunger and decrease food intake. The tidal wave of adoption, however, has come on the heels of its weight loss prowess. A recent study suggested adults taking Wegovy lose 15% of their weight over a year.
If the use of drugs like Wegovy and Ozempic continues to rise, I believe...
Today's Sponsors
Today's Sponsor